Drug intelligence / Profile preview

aci-12589

Development stage: Phase 1
Lead developer: AC Immune
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]MNI-1216 (also known as [18F]ACI-12589) is a radiopharmaceutical PET imaging agent developed for the in vivo detection of alpha-synuclein pathology in the brain. It is designed as a targeted radioligand that binds to alpha-synuclein aggregates, which are characteristic of neurodegenerative diseases such as Parkinson's disease and related synucleinopathies. The compound contains fluorine-18, a positron-emitting radioisotope suitable for PET imaging. Its primary use is investigational and focused on enabling non-invasive visualization and quantification of alpha-synuclein deposits to aid diagnosis and research into these disorders[2][3].

Other names: [18F]MNI-1216[18F]ACI-12589

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on aci-12589.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aci-12589.

Explore the full profile